Citius Oncology expands distribution network for LYMPHIR with Cencora

CRANFORD, N.J. - Citius Oncology, Inc. (NASDAQ:CTOR) announced Tuesday it has signed a distribution services agreement with Cencora, formerly AmerisourceBergen, to support the commercial launch of its FDA-approved immunotherapy LYMPHIR. The news comes as parent company Citius Pharmaceuticals (NASDAQ:CTXR), currently trading at $1.67, shows signs of potential upside according to InvestingPro Fair Value analysis.

The agreement adds Cencora as a wholesale distributor for LYMPHIR, which was approved by the FDA in August 2024 for treating relapsed or refractory cutaneous T-cell lymphoma (CTCL) in patients who have undergone at least one prior systemic therapy.

This distribution partnership follows a previously announced agreement and aims to enhance product availability for treatment centers nationwide.

"As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. While the company operates with moderate debt levels, InvestingPro analysis reveals analysts expect profitability this year, with 12 additional key insights available to subscribers.

LYMPHIR is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The therapy works by binding to IL-2 receptors on cell surfaces, causing diphtheria toxin fragments to enter cells and inhibit protein synthesis, resulting in cell death.

Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma where T-cells become cancerous and develop into skin lesions. The disease typically affects men twice as often as women and is usually first diagnosed in patients between 50 and 60 years of age.

Citius Oncology is a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR). The company acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except Japan and certain parts of Asia in 2021.

The information in this article is based on a company press release statement. Investors tracking this development should note that Citius Pharmaceuticals is scheduled to report its next earnings on August 13, 2025. For comprehensive financial analysis and detailed metrics, consider accessing InvestingPro’s extensive database of company insights and valuations.

In other recent news, Citius Pharmaceuticals has made notable changes to its corporate structure. The company has redeemed its one share of Series A Preferred Stock for $100, matching the original purchase price. In a strategic move to increase its share capital, Citius Pharmaceuticals filed a Certificate of Amendment with the Nevada Secretary of State, raising its authorized shares from 26 million to 260 million. This includes an increase in authorized common shares from 16 million to 250 million. The amendment was approved by the company’s stockholders at a special meeting, with 547,138,179 shares in favor and 457,549,494 against. The holder of the one outstanding share of Series A Preferred Stock was allowed to vote only on the amendment, with their votes cast proportionally to those of common stockholders. Additionally, a proposal to adjourn the meeting to solicit more proxies was rendered unnecessary as the amendment passed. These developments were announced through a press release, providing important information to shareholders and the public.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.